[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Koga F, Kawano K, Honda M, Sumi S, Horimi H, Kondo S, Yoshida K: Sarcomatoid renal cell carcinoma with scant carcinomatous components. Int J Urol; 2000 Feb;7(2):58-60; discussion 61
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid renal cell carcinoma with scant carcinomatous components.
  • A 30-year-old male underwent radical nephrectomy for a right renal tumor 15 cm in diameter.
  • On microscopic examination of initial 17 sections, the tumor consisted of pleomorphic giant cells and spindle neoplastic cells.
  • At that time a diagnosis of rhabdomyosarcoma of the kidney was made.
  • However, further microscopic examination of another eight sections revealed small areas of clear cell-type renal cell carcinoma (RCC) which transited to sarcomatous components and led to a diagnosis of sarcomatoid RCC.
  • The patient underwent three cycles of adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10710249.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  •  go-up   go-down


2. Shimomura T, Ikemoto I, Yamada H, Hayashi N, Ito H, Oishi Y: Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin. Int J Urol; 2005 Sep;12(9):835-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin.
  • We report a case of sarcomatoid renal cell carcinoma with a chromophobe component showing significant elevation of beta-human chorionic gonadotropin (beta-HCG) in the peripheral blood.
  • However, 3 months later, masses were discovered in the left renal bed and in the lung in association with elevated serum levels of beta-HCG.
  • The patient was rehospitalized and received combination therapy with interferon-alpha and doxorubicin-based multiple chemotherapy (cyclophosphamide, vincristine, doxorubicin, and dacarbazine).
  • The recurrent mass responded extremely well to treatment, and beta-HCG normalized.
  • However, the patient died 14 months after nephrectomy because of eventual resistance to chemotherapy.
  • Sarcomatoid renal cell carcinoma containing beta-HCG positive cells were pathologically diagnosed with immunohistochemical staining in the left kidney.
  • Sarcomatoid renal cell carcinoma is a variant of renal adenocarcinoma which has a poor prognosis.
  • This patient had an extremely rare sarcomatoid renal cell carcinoma associated with serum levels of beta-HCG which were elevated and strongly correlated with morphologic cancer activity. beta-HCG might be a useful serum marker for detecting and monitoring this renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Chorionic Gonadotropin, beta Subunit, Human / biosynthesis. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Urol. 2006 Jan;13(1):99
  • (PMID = 16201981.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


3. Beier D, Schuierer G, Beier CP, Bogdahn U: Short-term effective treatment of CNS metastasis of sarcomatoid renal cell carcinoma with temozolomide and pegylated liposomal doxorubicin: A case report. Cases J; 2008;1(1):210
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term effective treatment of CNS metastasis of sarcomatoid renal cell carcinoma with temozolomide and pegylated liposomal doxorubicin: A case report.
  • Sarcomatoid renal cell carcinoma represents high-grade transformation of different subtypes of renal cell carcinoma and is associated with a dismal prognosis and high resistance to chemotherapy.
  • We report on the course of disease of a 63 years old patient undergoing a nearly complete remission of multiple intracranial and spinal metastatic lesions of a sarcomatoid renal cell carcinoma by a combined chemotherapy with temozolomide and pegylated liposomal doxorubicin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):523-8 [10080595.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1313-8 [2441841.001]
  • [Cites] Urology. 1989 Nov;34(5):281-3 [2815451.001]
  • [Cites] Pathology. 1999 Aug;31(3):185-90 [10503259.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):271-4 [11300337.001]
  • [Cites] Int J Urol. 2005 Sep;12(9):835-7 [16201981.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):107-8 [15685046.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):38-43 [14769139.001]
  • (PMID = 18834519.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2567305
  •  go-up   go-down


Advertisement
4. Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas SP, Nichols KF, Stadler WM: A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer; 2008 Mar;6(1):21-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
  • BACKGROUND: Advanced renal cell cancer (RCC) continues to have a poor overall prognosis despite new FDA-approved therapies.
  • Although taxane-based therapies are generally ineffective in RCC, research into the role of the von Hippel-Lindau protein has shown an association with microtubule dynamics.
  • SB-715992 is a new agent that inhibits the function of a mitotic kinesin known as kinesin spindle protein and leads to cell death.
  • PATIENTS AND METHODS: Twenty patients with previously treated advanced RCC were enrolled on this phase II trial of SB-715992, with response rate as a primary endpoint.
  • Six patients had stable disease, and 1 patient continues on therapy after 12 cycles.
  • CONCLUSION: This dose and schedule of SB-715992 does not appear to have a significant cytotoxic effect for patients with previously treated advanced RCC.

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):64-70 [12510195.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):454-63 [14752067.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):2015-25 [15143095.001]
  • [Cites] J Urol. 2004 Jul;172(1):58-62 [15201737.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6367S-70S [15448032.001]
  • [Cites] Oncology (Williston Park). 1989 Jul;3(7):43-9; discussion 51-3 [2701811.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9 [8855223.001]
  • [Cites] JAMA. 1999 May 5;281(17):1628-31 [10235157.001]
  • [Cites] Exp Cell Res. 2004 Dec 10;301(2):139-46 [15530850.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):155-63 [15645438.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3439-45 [15867246.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):49-59 [16023598.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • (PMID = 18501078.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 CM062201; United States / NCI NIH HHS / CM / N01 CM062201; United States / PHS HHS / / N01CMS57018-16
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Quinazolines; BKT5F9C2NI / ispinesib
  • [Other-IDs] NLM/ NIHMS105214; NLM/ PMC2704464
  •  go-up   go-down


5. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M: Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation; 2002 May 27;73(10):1565-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunosuppressive drug therapy-induced impairment of the organ graft recipient's immune surveillance is considered to be the mechanism for the heightened incidence and metastatic progression.
  • We identified a cell-autonomous and host-immunity independent mechanism for cyclosporine-associated tumor progression.
  • METHODS: A spontaneously arising renal adenocarcinoma (renal cancer) of BALB/c origin was used as the model tumor.
  • The effect of rapamycin on renal cancer cell phenotype, molecules (E-cadherin, p27 kip1, cyclin D1) implicated in tumor progression, and the effect of rapamycin on in vivo tumor progression were explored in BALB/c mice and in T-cell, B-cell, and natural killer (NK) cell-deficient severe combined immune deficiency (SCID)-beige mice.
  • In the SCID-beige mice, T24 human bladder transitional cell carcinoma also was used as the tumor inoculum.
  • RESULTS: Rapamycin conditioning of renal cancer cells upregulated E-cadherin expression and induced phenotypic transition from invasive spindle, or dome-shaped cells, with exploratory pseudopodia to noninvasive cuboidal cells that formed cell-to-cell adhesions.
  • Rapamycin increased p27 kip1, reduced cyclinD1, and arrested the growth of renal cancer cells in G1/S phase.
  • Rapamycin treatment alone, or with cyclosporine, prolonged the survival of mice inoculated with renal cancer cells or T24 human bladder cancer cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibiotics, Antineoplastic / pharmacology. Carcinoma, Renal Cell / drug therapy. Immunosuppression. Immunosuppressive Agents / pharmacology. Kidney Neoplasms / drug therapy. Sirolimus / pharmacology
  • [MeSH-minor] Animals. B-Lymphocytes / immunology. Cadherins / genetics. Cell Cycle Proteins / genetics. Cyclin D1 / genetics. Cyclin-Dependent Kinase Inhibitor p27. DNA Primers. Disease Progression. Genes, Tumor Suppressor. Killer Cells, Natural / immunology. Mice. Mice, Inbred BALB C. Mice, SCID. T-Lymphocytes / immunology. Tacrolimus / pharmacology. Tumor Cells, Cultured. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12042641.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 26932
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cadherins; 0 / Cdkn1b protein, mouse; 0 / Cell Cycle Proteins; 0 / DNA Primers; 0 / Immunosuppressive Agents; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; W36ZG6FT64 / Sirolimus; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


6. Okada T, Tsukazaki H, Itoh M, Nishio Y, Muro H: [Sarcomatoid carcinoma of the renal pelvis: a case report]. Hinyokika Kiyo; 2002 Feb;48(2):75-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcomatoid carcinoma of the renal pelvis: a case report].
  • Unexpectedly, macroscopic examination of the resected kidney revealed multiple yellowish nodules located in the renal pelvis and calyces.
  • Histopathologically the nodules consisted of two pattern of malignancy, transitional cell carcinoma and spindle sarcomatous tumor.
  • Immunohistochemical examination showed that spindle cells were stained positive for cytokeratin, and the final diagnosis was sarcomatoid carcinoma of left renal pelvis.
  • Postoperatively, the patient underwent two courses of adjuvant chemotherapy, but metastases to retroperitoneal lymph nodes were noted two months after operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968731.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


7. Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, Karl A, Stief CG: Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res; 2010;15:287-91
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
  • BACKGROUND: Sarcomatoid renal cell cancer (RCC) is a distinct histological variant of RCC that is associated with rapid progression and a poor prognosis.
  • The optimal treatment for patients with sarcomatoid RCC remains to be defined.
  • We carried out a prospective, open-label study to investigate the efficacy and safety of sorafenib in patients after GD failure in sarcomatoid RCC.
  • METHODS: Fifteen patients with pure sarcomatoid RCC and objective progressive disease were treated with GD (gemcitabine 1500 mg/m², doxorubicine 50 mg/m² administered by weekly intravenous infusion) until progression of disease.
  • Tumor response was measured by physical examination and computerized tomography scans and evaluated according to Response Evaluation Criteria in Solid Tumors criteria.
  • RESULTS: Median time to progression (TTP) under GD was 6.6 months (range 0.8 - 8 months).
  • During GD treatment there were no remissions and 6 patients died from progressive disease.
  • During sorafenib therapy one patient had a partial remission lasting for 3 months and 4 patients experienced stable disease with a duration of 3 to 9 months.
  • Four patients immediately progressed on sorafenib treatment but had a slower dynamic of tumor progression than under GD.
  • Dosing in both treatment phases was generally well tolerated with manageable toxicities and no requirement for dose reduction.
  • CONCLUSIONS: Chemotherapy with GD was ineffective in our patients with pure sarcomatoid RCC.
  • Subsequent anti-angiogenic treatment using the multi-tyrosine kinase inhibitor sorafenib resulted in additional progression-free survival in 5 of 9 patients.
  • Further evaluation of targeted anti-angiogenic agents for the treatment of sarcomatoid RCC is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Deoxycytidine / analogs & derivatives. Doxorubicin / therapeutic use. Kidney Neoplasms / drug therapy. Pyridines / therapeutic use

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):177-86 [10768596.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2419-26 [10856102.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):271-4 [11300337.001]
  • [Cites] Urology. 2001 Dec;58(6):1058 [11744492.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):111-6 [11815966.001]
  • [Cites] J Urol. 2002 Sep;168(3):959-61 [12187199.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):113-7 [12720105.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2995-3002 [12784334.001]
  • [Cites] Eur Urol. 2003 Jul;44(1):65-75 [12814677.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):61-5 [12833456.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1611-9 [14534876.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1545-51 [15378501.001]
  • [Cites] Urology. 1989 Nov;34(5):281-3 [2815451.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):303-21 [8493752.001]
  • [Cites] Semin Oncol. 1995 Feb;22(1):42-60 [7855619.001]
  • [Cites] Eur Urol. 1995;27(2):138-41 [7744156.001]
  • [Cites] Eur J Cancer. 1994;30A(8):1064-7 [7654430.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):523-8 [10080595.001]
  • [Cites] Clin Genitourin Cancer. 2006 Mar;4(4):263-8 [16729909.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1273-9 [16909426.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Urologe A. 2007 Apr;46(4):406-11 [17160666.001]
  • [Cites] Eur Urol. 2007 Jun;51(6):1502-10 [17408850.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):127-31 [18165647.001]
  • [Cites] Oncology. 2007;73(3-4):204-9 [18418013.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):235-41 [19064974.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Jun;7(6):618-30 [19555584.001]
  • (PMID = 20696639.001).
  • [ISSN] 2047-783X
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0W860991D6 / Deoxycytidine; 25X51I8RD4 / Niacinamide; 80168379AG / Doxorubicin; 9ZOQ3TZI87 / sorafenib; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC3351952
  •  go-up   go-down


8. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer; 2004 Oct 1;101(7):1545-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
  • BACKGROUND: Immunotherapy is generally ineffective in patients with sarcomatoid renal cell carcinoma (RCC) and in patients with rapidly progressive metastatic or locally recurrent disease, with a median time to progression of approximately 2 months and a median survival of 4-7 months.
  • Gemcitabine-based regimens have modest antitumor activity, whereas doxorubicin is often used to treat sarcomatoid RCC.
  • Based on the antitumor activity of doxorubicin and gemcitabine in collecting duct carcinoma of the kidney, the authors used this combination to treat selected patients with sarcomatoid or rapidly progressing RCC.
  • METHODS: Eighteen patients (11 males and 7 females; median age, 53 years; range, 31-81 years) with RCC (56% sarcomatoid; 44% other) were treated at 2 institutions in a collaborative study that was not institutional review board reviewed.
  • Seven patients received previous treatment with interferon or interleukin-2.
  • Sites of metastases included the lung, soft tissue, bone, liver, and brain with 88% of patients having > or = 3 sites of disease.
  • Treatment consisted of doxorubicin (50 mg/m2) and gemcitabine (1500 or 2000 mg/m2) every 2-3 weeks with granulocyte-colony-stimulating factor support.
  • Therapy was well tolerated with no Grade 4 toxicities.
  • CONCLUSIONS: These data suggested that the combination of doxorubicin and gemcitabine has antitumor activity in patients with sarcomatoid RCC or with rapidly progressing RCC.
  • A prospective investigation of this combination in RCC is warranted.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Renal Cell / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Doxorubicin / administration & dosage. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15378501.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Recombinant Proteins; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


9. Fujiwara Y, Kiura K, Tabata M, Takigawa N, Hotta K, Umemura S, Omori M, Gemba K, Ueoka H, Tanimoto M: Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anticancer Drugs; 2008 Apr;19(4):431-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine.
  • A 60-year-old Japanese man presented to our hospital with a painful left hip.
  • Computed tomography showed a tumor in the left kidney and metastases in the left gluteus maximus muscle and lung.
  • The pathological diagnosis of a biopsy specimen obtained from a metastatic lesion in the left gluteus maximus muscle was sarcomatoid renal cell carcinoma.
  • This seriously ill patient suffering from advanced sarcomatoid renal cell carcinoma was treated with single-agent gemcitabine, resulting in symptom relief and a dramatic improvement in his status; all of the tumors had regressed significantly by the 11th dose of gemcitabine.
  • These findings indicate that single-agent gemcitabine is one of the few chemotherapeutic agents effective for palliation in patients with sarcomatoid renal cell carcinoma, even those with poor performance status.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Renal Cell / drug therapy. Deoxycytidine / analogs & derivatives. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Buttocks / pathology. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Male. Middle Aged. Muscle Neoplasms / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454054.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


10. Tickoo SK, Alden D, Olgac S, Fine SW, Russo P, Kondagunta GV, Motzer RJ, Reuter VE: Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol; 2007 Apr;177(4):1258-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
  • PURPOSE: Sarcomatoid renal cell carcinomas, highly aggressive variants of renal cell carcinoma subtypes, often present with or develop metastases soon after the primary diagnosis.
  • Most metastatic cases do not respond to immunotherapy or aggressive chemotherapy.
  • Recently targeted therapies, particularly those targeting hypoxia inducible pathway molecules, have been tested clinically on metastatic clear cell renal cell carcinoma with promising initial results.
  • No such studies are available on sarcomatoid renal cell carcinoma.
  • We investigated the hypoxia inducible pathway marker immunohistochemical expression profile, and any potential therapeutic implications that such expression may have, in these tumors.
  • MATERIALS AND METHODS: Immunohistochemical staining for hypoxia inducible factor-1alpha, glucose transporter 1, carbonic anhydrase IX and vascular endothelial growth factor was performed in 22 clear cell and 12 nonclear cell sarcomatoid renal cell carcinomas.
  • RESULTS: Most clear cell renal cell carcinomas over expressed (2+ or 3+) hypoxia inducible factor-1alpha (in 59%), carbonic anhydrase IX (95%), glucose transporter 1 (91%) and vascular endothelial growth factor (95%).
  • None of the nonclear cell sarcomatoid renal cell carcinomas showed 2+ or 3+ expression of hypoxia inducible factor-1alpha, carbonic anhydrase IX or glucose transporter 1, but 92% showed diffuse positivity for vascular endothelial growth factor.
  • Over expression of carbonic anhydrase IX showed no association with survival, unlike that reported in (nonsarcomatoid) clear cell renal cell carcinoma.
  • There was significant discordance in the staining grades among hypoxia inducible factor-1alpha, carbonic anhydrase IX and glucose transporter 1 in clear cell renal cell carcinoma, suggesting that mechanisms other than hypoxia inducible pathway may be involved in some sarcomatoid clear cell renal cell carcinoma.
  • CONCLUSIONS: Hypoxia inducible pathway markers continue to be over expressed in sarcomatoid clear cell renal cell carcinoma, and can be of diagnostic usefulness in such high grade tumors.
  • Over expression of vascular endothelial growth factor in the clear and nonclear cell groups raises the possibility that vascular endothelial growth factor targeted therapies may have a role in the management of sarcomatoid renal cell carcinoma, and deserve further investigation.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Kidney Neoplasms / metabolism
  • [MeSH-minor] Follow-Up Studies. Humans. Immunohistochemistry. Time Factors

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2007 Apr;177(4):1224 [17382693.001]
  • (PMID = 17382701.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


11. Hoshi S, Satoh M, Ohyama C, Hiramatu M, Watanabe R, Hagisawa S, Endo M, Arai Y: Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma. Int J Clin Oncol; 2003 Apr;8(2):113-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
  • Sarcomatoid renal cell carcinoma (SRCC) is associated with an aggressive course, high incidence of bone metastasis, and an extremely poor prognosis.
  • There are a few case reports concerning the effectiveness of chemotherapy on metastasis in SRCC.
  • We report a 22-year-old woman with an 8-cm x 7-cm left renal mass.
  • The pathological diagnosis was SRCC, INF-beta, pT3aN2.
  • Although, she received continuous infusion of interferon alpha-2a (INFalpha-2a) and interleukin-2 (IL-2) as adjuvant therapy, liver metastasis appeared 2 months later.
  • A computed tomography (CT) scan after the first cycle revealed that the multiple osteolytic bone tumors had significantly decreased in size.
  • A second course of chemotherapy, with gemcitabine and IL-2 was given, but it was ineffective, and the patient died approximately 16 months after the initial diagnosis of SRCC.
  • Combination chemotherapy with gemcitabine, docetaxel, and carboplatin was effective for the bone metastasis of SRCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Deoxycytidine / analogs & derivatives. Kidney Neoplasms / pathology. Paclitaxel / analogs & derivatives. Sarcoma / secondary. Taxoids
  • [MeSH-minor] Adult. Biopsy, Needle. Carboplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Nephrectomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12720105.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 30
  •  go-up   go-down


12. Bangalore N, Bhargava P, Hawkins MJ, Bhargava P: Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol; 2001 Feb;12(2):271-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature.
  • The sarcomatoid variant of renal-cell carcinoma (SRCC), a clinically aggressive subtype of renal parenchymal tumors, is typically resistant to systemic treatments and carries a poor prognosis.
  • The authors report a case of a 57-year-old male with advanced SRCC who had a durable complete response after MAID (mesna, adriamycin, ifosfamide and dacarbazine) chemotherapy, and remains free of disease four years after completing treatment.
  • To the authors' knowledge, this is the first report of a remission from MAID chemotherapy in SRCC.
  • A review of published literature revealed occasional responses after systemic chemotherapy.
  • Notably, all responses were seen with doxorubicin containing regimens, suggesting that doxorubicin is a critical component in chemotherapy regimens for SRCC.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11300337.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 22
  •  go-up   go-down


13. Rashid MH, Welsh CT, Bissada NK, Chaudhary UB: Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. Am J Clin Oncol; 2005 Feb;28(1):107-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma.
  • Sarcomatoid renal cell carcinoma (SRCC) is a heterogeneous disease with generally unreliable response to various therapies in clinical studies.
  • We illustrate a case report in which a woman with metastatic SRCC had a complete and durable response to adriamycin and ifosfamide chemotherapy.
  • [MeSH-major] Carcinoma, Renal Cell / classification. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interferons / therapeutic use. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685046.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 9008-11-1 / Interferons; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


14. Kuroda N, Hes O, Miyazaki E, Shuin T, Enzan H: Frequent expression of neuroendocrine markers in mucinous tubular and spindle cell carcinoma of the kidney. Histol Histopathol; 2006 01;21(1):7-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent expression of neuroendocrine markers in mucinous tubular and spindle cell carcinoma of the kidney.
  • Mucinous tubular and spindle cell carcinoma (MTSCC) is a new tumorous entity which has been recently established.
  • In normal kidney, distal tubules or collecting ducts were positive for NSE, but no structures were positive for chromogranin A or synaptophysin.
  • Finally, it is possible that MTSCC may be one of renal neoplasms which frequently exhibit the neuroendocrine differentiation.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma, Mucinous / chemistry. Carcinoma / chemistry. Chromogranins / analysis. Kidney Neoplasms / chemistry. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis
  • [MeSH-minor] Adult. Cell Proliferation. Chromogranin A. Female. Humans. Immunohistochemistry. Kidney / chemistry. Kidney / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16267782.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


15. Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Russo P, Feldman DR, Patil S, Motzer RJ: Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
  • : e16017 Background: Sarcomatoid-variant represents a spindle cell phenotype of RCC that can be present in any subtype, usually showing aggressive biological behavior.
  • MSKCC experience was studied to provide data on outcome and survival to systemic therapy for metastatic, sarcomatoid-variant RCC.
  • METHODS: Clinical features, treatment outcome and survival were reviewed in 63 pts with sarcomatoid-variant metastatic RCC from a database of 650 pts treated at MSKCC with systemic therapy (cytokines, anti-angiogenesis targeted therapy and chemotherapy).
  • Response to therapy, progression-free survival (PFS), and overall survival (OS) was determined for pts based on their first treatment at MSKCC.
  • The percentage of sarcomatoid component in the tumors was assessed.
  • RESULTS: Histology subtypes with sarcomatoid-variant among the 63 pts included 46 clear cell, 5 papillary, 5 chromophobe, 1 collecting duct, and 6 unclassified.
  • 34 pts received targeted therapy (29 sunitinib, 3 sorafenib, 2 temsirolimus), 20 pts received cytokine therapy (19 interferon, 1 interleukin) and 9 received other therapies.
  • Differences in PFS were observed based on therapy (sunitinib vs. all other) and histology (clear cell vs. non-clear cell).
  • The median PFS for sunitinib therapy was 4.4 months (95% CI 2.2-6.7) versus 2 months (95% CI 1.7-2.7) for all other therapies (p = 0.02); and 3 months (95% CI 2.3-4.5) for clear cell versus 1.6 months (95% CI 1.0-2.1) for non-clear cell histology (p = 0.007).
  • In a subset (n = 31) with available specimen, the median % sarcomatoid content was 20% (range 2%-100%).
  • No difference in PFS or OS was observed according to % sarcomatoid content.
  • CONCLUSIONS: Metastatic sarcomatoid-variant RCC is associated with a poor prognosis.
  • Sunitinib resulted in a modest response rate and longer PFS versus other therapies.
  • Studies to assess outcome, characterize tumor biology, and develop novel treatment strategies are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962911.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ferlicot S, Allory Y, Compérat E, Mege-Lechevalier F, Dimet S, Sibony M, Couturier J, Vieillefond A: Mucinous tubular and spindle cell carcinoma: a report of 15 cases and a review of the literature. Virchows Arch; 2005 Dec;447(6):978-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous tubular and spindle cell carcinoma: a report of 15 cases and a review of the literature.
  • Mucinous tubular and spindle cell carcinomas are low-grade renal epithelial neoplasms, which were first recognized as a specific entity in the World Health Organization 2004 classification.
  • We present 15 additional cases that were incidentally discovered in ten women and five men, with a mean age of 53 years.
  • The tumor is characteristically made up of large eosinophilic regular spindle cells separated by a myxoid stroma with intercellular alcian-blue-positive clear droplets.
  • In peripheral areas, elongated tubules and papillae covered by cubic cells are found.
  • Until this entity had been defined, pathologists used to classify these tumors as variants of solid papillary carcinomas with compressed and elongated papillae, metanephric adenomas, and sarcomatoid carcinomas.
  • In our 15 cases, immunohistochemistry favored a distal tubule origin (EMA(+), AE1/AE3(+), CK7(+), CK19(+), E-cadherin(+), AMACR(+), and CD10(-)).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / genetics. Carcinoma / pathology. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathologe. 2003 Oct;24(6):453-9 [14605851.001]
  • [Cites] Pathol Int. 2001 Dec;51(12):954-60 [11844069.001]
  • [Cites] Pathol Int. 1998 May;48(5):416-20 [9704350.001]
  • [Cites] Hum Pathol. 2001 May;32(5):506-12 [11381369.001]
  • [Cites] Histopathology. 2005 Aug;47(2):218-9 [16045786.001]
  • [Cites] Pathology. 2003 Dec;35(6):499-504 [14660100.001]
  • [Cites] Hum Pathol. 2002 May;33(5):574-5; author reply 575-6 [12094388.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1162-71 [12429795.001]
  • [Cites] Am J Med Genet. 2002 Oct 30;115(3):164-72 [12407697.001]
  • [Cites] Histopathology. 2002 Dec;41(6):549-55 [12460208.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):69-76 [14707866.001]
  • (PMID = 16231179.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


17. Shet T, Viswanathan S: The cytological diagnosis of paediatric renal tumours. J Clin Pathol; 2009 Nov;62(11):961-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cytological diagnosis of paediatric renal tumours.
  • Fine needle aspiration cytology (FNAC) is used for preoperative diagnosis of paediatric renal tumours, especially in centres where preoperative chemotherapy is advocated in Wilms' tumour.
  • This review focuses on salient cytological features in specific paediatric renal tumours, the approach to resolving a differential diagnosis and the role of ancillary methods in diagnosis of paediatric renal tumours.
  • Crucial differential diagnoses include distinguishing: Wilms' tumour from benign tumours in the kidney like multicystic nephroma or congenital mesoblastic nephroma; aggressive non-Wilms' tumours of kidney like rhabdoid tumour of kidney; and Wilms' tumour from other paediatric round cell sarcomas like neuroblastoma, non-Hodgkin lymphoma etc.
  • An approach based on classifying smears according to their cellular patterns as triphasic, round cell, spindle cell or epithelioid cell type assists in classifying paediatric renal tumours on cytology.
  • Immunocytochemistry for WT1, cytokeratin, synaptophysin, leucocyte common antigen and MIC2 will aid in evaluating round cell tumours in the renal region, while WT1, bcl2, vimentin and desmin will be useful for spindle cell tumours in that region.
  • A checklist of common tumours in a particular age group, relevant clinical information, awareness of distinctive and overlapping cytological features, and appropriate use of immunocytochemistry with cytogenetics go a long way in ensuring an accurate cytological diagnosis.
  • Used judiciously, FNAC is as effective a tool as a core biopsy for preoperative diagnosis of paediatric renal tumours, and with experience a 92% accuracy rate can be achieved.
  • [MeSH-minor] Adolescent. Age Distribution. Biopsy, Fine-Needle / methods. Carcinoma, Renal Cell / pathology. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Infant, Newborn. Nephroma, Mesoblastic / pathology. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology. Sarcoma, Ewing / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700411.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


18. Mainguené C, Choquenet C, Cucchi JM, Dupré F, Monticelli I, Michiels JF, de Pinieux G, Vieillefond A: [Primary pleomorphic rhabdomyosarcoma of the kidney in adults: unusual tumor]. Prog Urol; 2003 Sep;13(4):679-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Rhabdomyosarcome pléomorphe primitif du rein chez l'adulte: une tumeur rare.
  • The clinical signs associated with the flank tumoral syndrome, the histologic appearance of cytoplasmic double striation in rhabdomyoblasts and the immunohistochemical expression of skeletal muscle differentiation (desmin, myoglobin, myogenin) are described in the context of a rapidly evolving renal RMS in a 77-year old man.
  • The differential diagnosis are mainly represented by sarcomatoid renal cell carcinoma.
  • According to the neoplastic extent, the treatment includes radical nephrectomy, chemotherapy and surgery.
  • The prognosis of primary renal RMS is extremely poor, with lymph node, hepatic, bone marrow and pulmonary metastasis and a short survival rate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650305.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. García Mediero JM, Alonso Dorrego JM, Nuñez Mora C, Pastor Arquero T, De Fata FR, Cisneros Ledo J, Perez Mies B, Picazo García ML, de la Peña Barthel YJ: [Early-onset sarcomatoid renal carcinoma. Report of a new case and comparison of the same case with another appearing at a mature age]. Arch Esp Urol; 2002 Sep;55(7):843-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early-onset sarcomatoid renal carcinoma. Report of a new case and comparison of the same case with another appearing at a mature age].
  • [Transliterated title] Carcinoma renal sarcomatoide de temprana aparición. Aportación de un nuevo caso y comparación del mismo con otro de aparición en edad madura.
  • We also review etiological, diagnostic and therapeutic features.
  • RESULTS: Despite aggressive surgery and adjuvant chemotherapy it has a very poor prognosis, with disease progression within 6 months in both cases.
  • CONCLUSIONS: Sarcomatoid renal cell carcinoma is an infrequent entity, extremely aggressive and requires radical surgery at the time of diagnosis due to its advanced stage, although results are poor.
  • [MeSH-minor] Adult. Age of Onset. Aged. Antineoplastic Agents, Phytogenic / therapeutic use. Chemotherapy, Adjuvant. Disease Progression. Fatal Outcome. Female. Hepatectomy / methods. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Node Excision. Nephrectomy. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12380314.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


20. Radhika S, Bakshi A, Rajwanshi A, Nijhawan R, Das A, Kakkar N, Joshi K, Marwaha RK, Rao KL: Cytopathology of uncommon malignant renal neoplasms in the pediatric age group. Diagn Cytopathol; 2005 May;32(5):281-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of uncommon malignant renal neoplasms in the pediatric age group.
  • Malignant renal neoplasms are common solid tumors in pediatric oncology practice.
  • These include the common Wilms' tumor/nephroblastoma and the uncommon neoplasms such as clear-cell sarcoma of the kidney (CCSK), rhabdoid tumor, renal-cell carcinoma, and others.
  • The aim of this study was to describe in detail the cytopathological features of the histopathologically proven uncommon pediatric renal tumors.
  • Aspirates from Wilms' tumor, which are mesenchyme predominant, show clusters of spindle cells associated with the matrix material.
  • CCSK, classic subtype, is characterized by round to oval cells arranged perivascularly and also in sheets and clusters intimately associated with a metachromatic matrix mucopolysaccharide material better appreciated in May-Grunwald-Giemsa (MGG)-stained smears.
  • Spindle-cell pattern of CCSK is difficult to diagnose on aspiration cytology.
  • Renal-cell carcinoma of childhood shows similar cytological features as its adult counterpart.
  • Further, non-Wilms' renal malignant neoplasms must be distinguished from the common Wilms' tumor so that appropriate chemotherapy protocols may be instituted in cases where the tumor is in an advanced stage of malignancy.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Renal Cell / pathology. Endodermal Sinus Tumor / pathology. Kidney Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology
  • [MeSH-minor] Adolescent. Cell Nucleus / pathology. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Staining and Labeling. Wilms Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15830360.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Okoń K: Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis. Pol J Pathol; 2008;59(3):129-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis.
  • Malignant renal tumors constitute 3% of human cancers, although their frequency differs greatly in various areas.
  • Since the fifties, the incidence of renal cancers has been increasing, but at the some time the prognosis has been improving.
  • In particular, in the last years, several new treatment modalities have been introduced, relying on the understanding of renal cancer biology.
  • The identified etiological factors include smoking, increased body mass, dietary factors and chronic renal disease.
  • There are several renal tumor types differing in morphology, molecular genetics and biology.
  • Inactivation of the VHL gene leads to formation of the most frequent form in adults, namely clear cell carcinoma.
  • Papillary carcinomas depend mainly on the HGF receptor gene (c-Met) activating mutations.
  • At least two types of papillary carcinomas exist, which have different morphology and prognosis.
  • The molecular biology of chromophobe carcinoma and oncocytoma is poorly understood.
  • Differential diagnosis of these tumors is particularly difficult and may require extensive immunohistochemical and molecular studies.
  • Collecting duct carcinoma and medullary carcinoma are extremely aggressive but rare tumors.
  • Some renal tumors have been described or recognized only relatively recently; these newer entities include multilocular cystic clear cell carcinoma, spindle cell papillary mucinous carcinoma, tubulocystic carcinoma, renal epithelial and stromal tumor, epithelioid and oncocytic angiomyolipoma.
  • The improved prognosis in renal cancer depends on earlier detection, but also on refinement of therapeutic methods.
  • Renal carcinoma is notorious for its low sensitivity to chemotherapy and radiotherapy.
  • For several years, immunological treatment with IL-2 and INF-alpha was the only adjuvant therapy method.
  • However, recently several new drugs have been introduced; they act on tyrosine-kinase receptors, VEGF, c-Met or mTOR pathway.
  • With this progress, perfect understanding of renal tumor biology and exact histological diagnosis have become of prime practical importance.


22. Escudier B, Droz JP, Rolland F, Terrier-Lacombe MJ, Gravis G, Beuzeboc P, Chauvet B, Chevreau C, Eymard JC, Lesimple T, Merrouche Y, Oudard S, Priou F, Guillemare C, Gourgou S, Culine S, Genitourinary Group of the French Federation of Cancer Centers: Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol; 2002 Sep;168(3):959-61
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.
  • PURPOSE: We assessed the efficacy and toxicity of a chemotherapy regimen combining doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma.
  • Median time to progression was 2.2 months and median overall survival was 3.9 months.
  • CONCLUSIONS: The results do not support the standard use of doxorubicin/ifosfamide chemotherapy in patients with metastatic sarcomatoid renal cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology


23. Lekili M, Muezzinoglu T, Nese N, Temeltas G: Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation. J Chin Med Assoc; 2010 May;73(5):262-4
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
  • Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to urology practice.
  • The drugs used for management are used in a very limited number of patients and only for clear cell histology.
  • We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal cell carcinoma of clear cell histology.
  • We found that our results were different from those of previously reported studies, because sarcomatoid differentiation was evident in a histological examination of this case.
  • This case report might provide evidence that antiangiogenic agents may be active in any histological type of renal cell carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Pyridines / therapeutic use. Sarcoma / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20685594.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


24. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI: Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol; 2009 Jan 10;27(2):235-41
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
  • PURPOSE: Metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation is an aggressive disease that is associated with poor outcomes to chemotherapy or immunotherapy.
  • The utility of vascular endothelial growth factor (VEGF)-targeted therapy in patients with this disease is unknown.
  • PATIENTS AND METHODS: Patients who had mRCC with sarcomatoid features in the primary tumor and who were treated with VEGF-targeted therapy were retrospectively identified.
  • Pathology slides were reviewed to determine the percentage of sarcomatoid differentiation.
  • RESULTS: Forty-three patients who had sarcomatoid mRCC were identified.
  • The median percentage of sarcomatoid features was 14% (range, 3% to 90%).
  • Partial responses were limited to patients who had underlying clear-cell histology and less than 20% sarcomatoid elements.
  • Median tumor shrinkage was -2% (range, -85% to 127%), and 53% achieved some degree of tumor shrinkage on therapy.
  • CONCLUSION: Patients who have mRCC and sarcomatoid differentiation can demonstrate objective responses and tumor shrinkage to VEGF-targeted therapy.
  • Patients who have clear-cell histology and a lower percentage of sarcomatoid differentiation may have better outcomes with VEGF-targeted therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Benzenesulfonates / therapeutic use. Bevacizumab. Drug Delivery Systems. Female. Humans. Indoles / administration & dosage. Indoles / therapeutic use. Male. Middle Aged. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / therapeutic use. Pyrroles / administration & dosage. Pyrroles / therapeutic use. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064974.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


25. Tanaka K, Hara I, Takenaka A, Kawabata G, Fujisawa M: Incidence of local and port site recurrence of urologic cancer after laparoscopic surgery. Urology; 2008 Apr;71(4):728-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included 162 radical prostatectomies, 67 radical nephrectomies, 20 partial nephrectomies, 45 nephroureterectomies, 5 retroperitoneal lymph node dissections of testicular cancers after chemotherapy, 3 radical cystectomies, and 2 other procedures.
  • No patients without a histologic diagnosis of cancer were included in this study.
  • RESULTS: Of the 304 patients with cancer, 4 (1.3%) developed a local recurrence, including after retroperitoneal lymph node dissection in 2 patients, radical nephrectomy in 1, and radical cystectomy in 1.
  • The histologic type of both testicular cancers was mixed germ cell tumor, with one occurring in a renal hilar lymph node and the other in a paraaortic lymph node and kidney.
  • The histologic type of the renal cell carcinoma was papillary renal cell carcinoma with sarcomatoid features (Stage pT3aN1), and it occurred in a retrocaval lymph node.
  • The histologic type of the bladder cancer was transitional cell carcinoma, Grade 3, Stage pT4aN0, and it presented as peritoneal carcinomatosis 11 months postoperatively.
  • However, two recurrences were found in 5 patients who had undergone retroperitoneal lymph node dissection for testicular cancer after chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279936.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Bannowsky A, Leuschner I, Schiller H, Bothe K, Osmonov D, Jünemann KP, Hautmann S: [Sarcomatoid renal cell carcinoma. A rare and aggressive variation of primary renal cell carcinoma]. Urologe A; 2007 Apr;46(4):406-11
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcomatoid renal cell carcinoma. A rare and aggressive variation of primary renal cell carcinoma].
  • [Transliterated title] Das sarkomatoide Nierenzellkarzinom. Eine seltene und aggressive Variante des primären Nierenzellkarzinoms.
  • Every year, renal cell carcinoma (RCC) is responsible for the highest proportion of cancer-associated deaths in relation to all other malignant urological diseases.
  • Initially called carcinosarcoma, the sarcomatoid differentiation confers higher aggressiveness on any of the different subtypes of RCC, with a frequency of ca. 1%.
  • The presence of a sarcomatoid component makes the disease locally aggressive, which typically presents an advanced grade that is associated with fast progression and fatal outcome in a vast proportion of cases, with median survival lower than 1 year.
  • This is important for predicting the outcome for patients undergoing nephrectomy due to RCC, since chemotherapy in a certain group of patients with progressive disease can be a reasonable alternative to the failure of immunotherapy in sarcomatoid renal carcinoma.
  • We report our experience with sarcomatoid RCC in four patients with extensive tumor progression in comparison to the literature.
  • [MeSH-major] Carcinoma, Renal Cell / classification. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / classification. Kidney Neoplasms / diagnosis. Sarcoma / classification. Sarcoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Rare Diseases / diagnosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):523-8 [10080595.001]
  • [Cites] Cancer. 1983 Sep 1;52(5):899-903 [6871830.001]
  • [Cites] Cancer. 1968 Sep;22(3):556-63 [4299778.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1313-8 [2441841.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):107-8 [15685046.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1545-51 [15378501.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):516-26 [3791160.001]
  • [Cites] Int Braz J Urol. 2005 Jan-Feb;31(1):10-6 [15763002.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):435-41 [15087662.001]
  • (PMID = 17160666.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Larkin J, Fisher R, Pickering L, Thway K, Livni N, Fisher C, Gore M: Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib. J Clin Oncol; 2010 Oct 1;28(28):e539-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma, Renal Cell / drug therapy. Indoles / therapeutic use. Kidney Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20679595.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down






Advertisement